



# Metastatic only primitive neuroectodermal tumor: smoke without fire can be more dangerous

Jesse Rappaport, Usman Ahmad

Department of Cardiothoracic Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA

*Correspondence to:* Usman Ahmad, MD, FACS. Department of Cardiothoracic Surgery, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, J4-1, Cleveland, OH 44195, USA. Email: ahmadu@ccf.org.

*Comment on:* Mizelle J, Yang J, Burks E, *et al.* Case report of primitive neuroectodermal tumor with an unknown primary presenting with multiple lung metastasis. *Curr Chall Thorac Surg* 2019;1:15.

Received: 06 December 2019; Accepted: 25 December 2019; Published: 25 February 2020.

doi: 10.21037/ccts.2019.12.06

View this article at: <http://dx.doi.org/10.21037/ccts.2019.12.06>

Multiple, diffuse, well circumscribed large pulmonary nodules as an incidental finding is pathognomonic for disseminated cancer. For all cancers, the lung is the second most common site of metastasis after the liver (1,2) and the most common for Ewing Sarcoma family of tumors (ESFT) (3). Disseminated disease at presentation signifies poor prognosis regardless of the cancer origin, however both the treatment regimen and treatment response as well as the ultimate outcome is highly dependent on the type of metastatic cancer, and thus the first step is to obtain tissue diagnosis. While less invasive strategies always appear to be less morbid, they can be non-diagnostic and prolong time to treatment. Definitive surgical biopsies are invasive but conclusive and, despite slightly higher morbidity, end up being more effective.

The pathologist's role in investigative oncology cannot be underestimated in these difficult cases. In the case presented, the pathologists were able to determine the presence of the *EWSR1* leading towards further investigation of an osseous primary. The possible location of interosseous primary based on PET-CT and MRI, while certainly unlikely, is potentially more plausible in the adult patient population with what seems like a wider variety of disease characteristics with higher rates of soft tissue primaries and unconventional locations based on a review of patients over 50 (4). Treatment analysis in adults has many limitations relating to the lower numbers in an already rare disease, however the rates of disease free and overall survival are similar to those found in children (5-7). Regardless of primary location, the mainstay of treatment in metastatic disease, as was sought by the authors, is

systemic with potential addition of whole lung irradiation. The relatively small size of the primary tumor with limited primary metastatic disease to the lung alone carries a better prognostic indicator than additionally disseminated disease (8,9).

Interestingly, there is importance to be placed on long term follow up of the pulmonary lesions and further assessment by thoracic surgery after completion of chemotherapy. In both the pediatric and adult populations there is wide variability in the response rate of pulmonary metastasectomy dependent on the type of cancer (10). For the Ewing sarcoma pediatric population, the data is minimal and mixed, leading to no clear-cut role for metastasectomy at this time (11-13). Careful consideration of both patient and tumor factors is required for optimal patient selection when considering pulmonary metastasectomy (14).

The authors should be congratulated on their investigative work towards finding a finite diagnosis for their patient and should be charged with keeping good follow up to provide all viable options for treatment based upon treatment response. Long term follow up would be quite interesting as it may end up revealing the primary lesion.

## Acknowledgments

*Funding:* None.

## Footnote

*Provenance and Peer Review:* This article was commissioned

by the editorial office, *Current Challenges in Thoracic Surgery*. The article did not undergo external peer review.

**Conflicts of Interest:** Both authors have completed the ICMJE uniform disclosure form (available at <https://ccts.amegroups.com/article/view/10.21037/ccts.2019.12.06/coif>). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

- Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. *J Thorac Cardiovasc Surg* 1997;113:37-49.
- Pastorino U. The development of an international registry. *J Thorac Oncol* 2010;5:S196-7.
- Horowitz ME, Malawer MM, Woo SY, et al. Ewing's sarcoma family of tumors: ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Pizzo PA, Poplack DG. editors. *Principles and Practices of Pediatric Oncology*. 3rd. Philadelphia: Lippencott-Raven, 1997;831-88.
- Rochefort P, Italiano A, Laurence V, et al. A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. *Sci Rep* 2017;7:17917.
- Bacci G, Ferrari S, Comandone A, et al. Neoadjuvant Chemotherapy for Ewing's Sarcoma of Bone in Patients Older than Thirty-nine Years: Experience of Twenty-three Cases at the Istituto Ortopedico Rizzoli. *Acta Oncol* 2000;39:1111-6.
- Valdes M, Nicholas G, Verma S, et al. Systemic Therapy Outcomes in Adult Patients with Ewing Sarcoma Family of Tumors. *Case Rep Oncol* 2017;10:462-72.
- Scurr M, Judson I. How to treat the Ewing's family of sarcomas in adult patients. *Oncologist* 2006;11:65-72.
- Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. *J Clin Oncol* 2015;33:3036-46.
- Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. *European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol* 1998;9:275-81.
- Petrella F, Diotti C, Rimessi A, et al. Pulmonary metastasectomy: an overview. *J Thorac Dis* 2017;9:S1291-8.
- Letourneau PA, Shackett B, Xiao L, et al. Resection of pulmonary metastases in pediatric patients with Ewing sarcoma improves survival. *J Pediatr Surg* 2011;46:332-5.
- Raciborska A, Bilka K, Rychłowska-Pruszyńska M, et al. Management and follow-up of Ewing sarcoma patients with isolated lung metastases. *J Pediatr Surg* 2016;51:1067-71.
- Heaton TE, Davidoff AM. Surgical treatment of pulmonary metastases in pediatric solid tumors. *Semin Pediatr Surg* 2016;25:311-7.
- Handy JR, Bremner RM, Crocenzi TS, et al. Expert consensus document on pulmonary metastasectomy. *Ann Thorac Surg* 2019;107:631-49.

doi: 10.21037/ccts.2019.12.06

**Cite this article as:** Rappaport J, Ahmad U. Metastatic only primitive neuroectodermal tumor: smoke without fire can be more dangerous. *Curr Chall Thorac Surg* 2020;2:2.